Table 2.
Lipid and Lipoprotein Measures at Baseline and at 12 Months, According to Randomized Treatment Arm*
| Baseline | 12 monthsa | Changeb | Percent Change | ||
|---|---|---|---|---|---|
| LDL cholesterol–mg/dL | Placebo | 110 (96, 119) | 111 (96, 125) | 3 (–8, 15) | 2.7 (–7.4, 14.4) |
| Rosuvastatin | 109 (96, 120) | 55 (44, 71) | –51 (–64, –31) | –49.0 (–58.2, –32.7) | |
| HDL cholesterol–mg/dL | Placebo | 49 (41, 60) | 50 (42, 61) | 1 (–3, 5) | 1.7 (–6.7, 10.8) |
| Rosuvastatin | 49 (41, 59) | 52 (43, 64) | 3 (–1, 8) | 6 (–3, 17) | |
| Triglycerides–mg/dL | Placebo | 119 (87, 168) | 119 (89, 166) | 2 (–24, 25) | 1.2 (–18.4, 24.7) |
| Rosuvastatin | 120 (88, 171) | 102 (77, 139) | –17 (–48, 5) | –15.4 (–32.8, 5.3) | |
| Triglyceride/HDL cholesterol ratio | Placebo | 2.4 (1.5, 3.9) | 2.4 (1.6, 3.7) | –0.01 (–0.6, 0.5) | –0.3 (–22.6, 28.1) |
| Rosuvastatin | 2.4 (1.6, 3.9) | 1.9 (1.3, 3.0) | –0.4 (–1.2, 0.1) | –21.0 (–39.4, 3.0) | |
| Non-HDL cholesterol–mg/dL | Placebo | 135 (121, 147) | 138 (121, 154) | 3 (–9, 16) | 2.4 (–6.3, 12.0) |
| Rosuvastatin | 135 (121, 148) | 77 (65, 96) | –56 (–71, –34) | –42.7 (–51.0, –27.6) | |
| Apolipoprotein B–mg/dL | Placebo | 110 (97, 122) | 106 (93, 119) | –3 (–13, 7) | –2.9 (–11.6, 6.3) |
| Rosuvastatin | 110 (97, 123) | 66 (57, 81) | –42 (–54, –27) | –39.4 (–47.6, –26.7) | |
| LPIR score | Placebo | 51 (35, 67) | 53 (35, 69) | 1 (–8, 10) | 2.8 (–15.1, 23.9) |
| Rosuvastatin | 52 (35, 68) | 49 (34, 65) | –2 (–11, 7) | –3.2 (–20.6, 16.9) | |
| Total LDL particles–nmol/l | Placebo | 1281 (1089, 1476) | 1224 (1044, 1427) | –52 (–197, 95) | –4.2 (–14.6, 8.2) |
| Rosuvastatin | 1274 (1101, 1484) | 771 (633, 964) | –487 (–674, –283) | –39.6 (–49.4, –24.6) | |
| Large | Placebo | 457 (306, 602) | 438 (276, 586) | –20 (–143, 103) | –5.3 (–31.1, 27.3) |
| Rosuvastatin | 462 (304, 600) | 175 (93, 306) | –238 (–392, –70) | –57.5 (–77.3, –24.2) | |
| Small | Placebo | 611 (448, 841) | 596 (440, 828) | –14 (–159, 127) | –2.6 (–22.9, 23.2) |
| Rosuvastatin | 608 (446, 848) | 494 (374, 625) | –127 (–318, 19) | –22.0 (–42.8, 4.7) | |
| IDL | Placebo | 151 (96, 220) | 139 (85, 201) | –14 (–83, 56) | –10.6 (–45.4, 49.1) |
| Rosuvastatin | 157 (99, 225) | 83 (52, 124) | –68 (–138, –4) | –46.0 (–69.4, –4.5) | |
| LDL particle average size–nm | Placebo | 21.0 (20.5, 21.4) | 21.0 (20.5, 21.3) | 0 (–0.3, 0.3) | 0 (–1.5, 1.4) |
| Rosuvastatin | 21.0 (20.5, 21.4) | 20.6 (20.2, 21.0) | –0.3 (–0.8, 0.1) | –1.5 (–3.7, 0.5) | |
| Total VLDL particles–nmol/l | Placebo | 43.8 (30.1, 58.5) | 44.0 (31.0, 60.8) | 1.2 (–10.0, 13.0) | 3.5 (–21.8, 35.4) |
| Rosuvastatin | 43.3 (29.9, 58.8) | 33.8 (23.5, 46.7) | –8.5 (–20.4, 3.2) | –19.6 (–40.6, 10.3) | |
| Large | Placebo | 2.8 (1.3, 4.9) | 2.9 (1.3, 5.6) | 0.2 (–1.0, 1.6) | 8.0 (–35.7, 76.5) |
| Rosuvastatin | 2.8 (1.4, 5.0) | 2.2 (1.1, 4.2) | –0.3 (–1.7, 0.7) | –15.4 (–50.0, 40.0) | |
| Medium | Placebo | 11.8 (6.8, 18.6) | 13.6 (7.6, 22.4) | 1.9 (–3.2, 8.0) | 16.6 (–26.6, 86.8) |
| Rosuvastatin | 11.6 (6.8, 18.6) | 10.9 (6.5, 17.1) | –0.7 (–6.0, 4.4) | –7.0 (–43.0, 52.2) | |
| Small | Placebo | 27.1 (17.3, 38.1) | 25.0 (16.3, 36.4) | –1.4 (–12.0, 9.2) | –6.1 (–37.6, 43.2) |
| Rosuvastatin | 26.6 (17.0, 38.5) | 19.4 (12.4, 28.0) | –6.9 (–17.4, 3.0) | –26.7 (–53.2, 16.4) | |
| VLDL particle average size–nm | Placebo | 49.0 (44.2, 53.7) | 49.3 (44.6, 54.9) | 0.6 (–3.7, 5.0) | 1.3 (–7.3, 10.9) |
| Rosuvastatin | 49.0 (44.3, 54.1) | 50.2 (46.1, 55.1) | 1.4 (–3.0, 5.9) | 2.8 (–5.8, 12.7) | |
| VLDL triglycerides–mg/dL | Placebo | 62.3 (42.7, 87.7) | 64.0 (44.2, 94.0) | 3.1 (–12.1, 20.2) | 5.6 (–18.8, 35.8) |
| Rosuvastatin | 62.3 (43.5, 88.3) | 51.6 (36.5, 74.5) | –9.0 (–26.0, 5.5) | –15.2 (–35.9, 11.3) | |
| HDL particles–μmol/l | Placebo | 32.3 (28.5, 36.7) | 31.6 (27.8, 35.6) | –0.9 (–3.4, 1.7) | –3.0 (–10.1, 5.4) |
| Rosuvastatin | 32.4 (28.5, 36.5) | 33.7 (29.8, 38.0) | 1.3 (–1.5, 4.3) | 4.1 (–4.5, 13.9) | |
| Very large | Placebo | 2.0 (1.1, 3.5) | 1.9 (1.0, 3.5) | –0.1 (0.7, 0.6) | –2.3 (–31.3, 33.3) |
| Rosuvastatin | 2.0 (1.1, 3.4) | 2.5 (1.4, 4.2) | 0.5 (–0.3, 1.3) | 22.9 (–12.4, 74.1) | |
| Large | Placebo | 5.6 (4.2, 7.5) | 5.4 (4.0, 7.2) | –0.2 (–1.7, 1.1) | –4.5 (–26.6, 23.7) |
| Rosuvastatin | 5.7 (4.1, 7.5) | 5.7 (4.3, 7.5) | 0.1 (–1.5, 1.6) | 1.1 (–23.2, 33.2) | |
| Medium | Placebo | 4.8 (3.0, 7.0) | 4.6 (2.7, 6.8) | –0.3 (–2.4, 1.9) | –8.6 (–42.1, 50.6) |
| Rosuvastatin | 4.8 (3.0, 7.0) | 5.5 (3.4, 7.9) | 0.6 (–1.7, 3.0) | 12.5 (–30.6, 79.2) | |
| Small | Placebo | 5.0 (3.0, 7.7) | 5.8 (3.3, 8.7) | 0.6 (–1.8, 3.1) | 10.9 (–32.8, 80.1) |
| Rosuvastatin | 4.9 (2.9, 7.5) | 6.5 (3.8, 9.8) | 1.3 (–1.2, 4.3) | 28.6 (–22.4, 112.4) | |
| Very small | Placebo | 13.2 (10.5, 16.0) | 12.2 (9.5, 14.9) | –1.0 (–3.3, 1.2) | –7.6 (–23.1, 10.0) |
| Rosuvastatin | 13.3 (10.5, 15.9) | 11.7 (8.6, 14.7) | –1.5 (–4.0, 0.9) | –11.4 (–29.0, 7.1) | |
| HDL particle average size–nm | Placebo | 9.0 (8.6, 9.3) | 9.0 (8.6, 9.3) | 0 (–0.2, 0.2) | 0 (–2.2, 2.2) |
| Rosuvastatin | 9.0 (8.6, 9.3) | 9.1 (8.7, 9.5) | 0.1 (–0.1, 0.3) | 1.2 (–1.0, 3.6) |
To convert values for LDL (low-density lipoprotein), IDL (intermediate-density lipoprotein), VLDL (very low-density lipoprotein), HDL (high-density lipoprotein), and non-HDL cholesterol [calculated as the difference between total cholesterol and HDL cholesterol] to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
P values from the Wilcoxon signed rank test comparing baseline and 12 months values were statistically different (P<0.001), with the exception of triglycerides (P=0.17), triglyceride/HDL cholesterol ratio (P=0.74), very large HDL particles (P=0.002), and HDL particle average size (P=0.99) in the placebo group; and, among very large HDL particles (P=0.05) in the rosuvastatin group.
P values from Wilcoxon rank sum test comparing change among the rosuvastatin group with change among the placebo group were p<0.001 for all. Values obtained from individuals with baseline and 12-month measurements (N=9,180).